Next Article in Journal
Pharmacy Internal Controls: A Call for Greater Vigilance during the COVID-19 Pandemic
Previous Article in Journal
Cultural Humility: A Proposed Model for a Continuing Professional Development Program
Article

Clinical Evaluation of Basal-Bolus Therapy Delivered by the V-Go® Wearable Insulin Delivery Device in Patients with Type 2 Diabetes: A Retrospective Analysis

1
Bull Family Diabetes Center, Premier Health, Dayton, OH 45409, USA
2
Zealand Pharma US Inc., Boston, MA 02210, USA
3
School of Pharmacy, Cedarville University, Cedarville, OH 45314, USA
*
Author to whom correspondence should be addressed.
Pharmacy 2020, 8(4), 215; https://doi.org/10.3390/pharmacy8040215
Received: 27 October 2020 / Accepted: 11 November 2020 / Published: 14 November 2020
Insulin therapy is frequently required to achieve glycemic targets (A1c) in type 2 diabetes (T2D); however, clinicians and patients face barriers with the complexities of multiple daily injection regimens. Patch-like wearable insulin devices, such as V-Go, may simplify and optimize this complexity. This study evaluated the change in A1C and insulin total daily dose (TDD) in a suboptimally-controlled (not achieving A1C targets) T2D population after switching to V-Go. A retrospective chart analysis at a diabetes clinic was performed to evaluate change in A1c measurements from baseline (V-Go initiation) to end of study observation. Of the 139 patients enrolled, A1C significantly decreased from baseline (−1.5 ± 1.79%; p < 0.001). Patients prescribed insulin at baseline (n = 122) used significantly less insulin TDD (−8 u/day; p = 0.006). The percentage of patients meeting the target of A1C < 8% increased from 14% at baseline to 48% at study completion (p = 0.008). Patients prescribed a basal-bolus regimen prior to V-Go achieved an A1C reduction of 1.5 ± 2.0% (p < 0.0001) and experienced the greatest reduction in TDD (−24 u/day; p < 0.0001). Thus, patients switching to V-Go from a variety of therapies at baseline experienced reductions in A1C while using less insulin, with a reduction in clinically relevant hypoglycemia, indicating the potential benefit of V-Go in optimizing and simplifying T2D care. View Full-Text
Keywords: type 2 diabetes; V-Go; glycemic control; insulin; hemoglobin A1c type 2 diabetes; V-Go; glycemic control; insulin; hemoglobin A1c
Show Figures

Figure 1

MDPI and ACS Style

Zeidan, T.; Nikkel, C.; Dziengelewski, B.; Wu, S.; Chen, A.M.H. Clinical Evaluation of Basal-Bolus Therapy Delivered by the V-Go® Wearable Insulin Delivery Device in Patients with Type 2 Diabetes: A Retrospective Analysis. Pharmacy 2020, 8, 215. https://doi.org/10.3390/pharmacy8040215

AMA Style

Zeidan T, Nikkel C, Dziengelewski B, Wu S, Chen AMH. Clinical Evaluation of Basal-Bolus Therapy Delivered by the V-Go® Wearable Insulin Delivery Device in Patients with Type 2 Diabetes: A Retrospective Analysis. Pharmacy. 2020; 8(4):215. https://doi.org/10.3390/pharmacy8040215

Chicago/Turabian Style

Zeidan, Trisha, Carla Nikkel, Beth Dziengelewski, Stephanie Wu, and Aleda M.H. Chen 2020. "Clinical Evaluation of Basal-Bolus Therapy Delivered by the V-Go® Wearable Insulin Delivery Device in Patients with Type 2 Diabetes: A Retrospective Analysis" Pharmacy 8, no. 4: 215. https://doi.org/10.3390/pharmacy8040215

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop